Global Hereditary Angioedema Therapeutics Market Valuation and Growth Prospects: $15.84 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary angioedema therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Hereditary Angioedema Therapeutics Market Size?

The hereditary angioedema therapeutics market has experienced rapid growth in recent years. It is projected to expand from $6.68 billion in 2024 to $7.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.3%. This historic growth can be attributed to factors like improved diagnosis and awareness, increased treatment access, research and development initiatives, patient advocacy and education, and favorable regulatory approvals.

The hereditary angioedema therapeutics market is anticipated to undergo significant expansion over the next few years. Its valuation is projected to reach $15.84 billion by 2029, exhibiting a robust compound annual growth rate (CAGR) of 19.5%. This growth during the forecast period stems from advancements in targeted therapies, the broadening scope of the global market, ongoing developments in gene therapy, evolving personalized medicine trends, and increased collaboration in research and treatment efforts. Prominent trends for this period include global access initiatives, a focus on health economic outcomes research, the implementation of early intervention strategies, and the development of pediatric HAE therapeutics.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Core Market Drivers Are Expanding The Hereditary Angioedema Therapeutics Industry?

The increasing occurrence of hereditary angioedema is anticipated to propel the growth of the hereditary angioedema market in the foreseeable future. Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent episodes of severe swelling affecting the skin and mucous membranes. This swelling is caused by an excess fluid build-up (EDEMA) and can manifest anywhere in the body, including the hands and feet, face, intestines, and airways. For instance, in June 2022, according to Rare Disease Advisor, an online resource for healthcare professionals, approximately 1 in every 50,000 persons globally suffer from hereditary angioedema, with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes lead to 15,000 to 30,000 emergency room visits each year in the US. Furthermore, 5.8% of HAE cases had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is a key factor driving the expansion of the hereditary angioedema market.

What Segment Insights Are Highlighted In The Hereditary Angioedema Therapeutics Market Report?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

Which Notable Trends Are Transforming The Hereditary Angioedema Therapeutics Market Outlook?

A significant trend gaining traction in the hereditary angioedema therapeutics market involves product innovations. Major companies within this market are actively developing pioneering products like ligand-conjugated (LICA) investigational antisense medicine and gene therapy to secure their market standing. For instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, unveiled NTLA-2002, an Investigational New Drug (IND), which received approval from the United States Food and Drug Administration for the treatment of hereditary angioedema. This approval permits the inclusion of the US in the worldwide Phase 2 part of the company’s ongoing Phase 1/2 trial. Following a single therapeutic dose, the inactivation of the target gene, kallikrein B1 (KLKB1), is intended to permanently decrease plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is considered a candidate for in vivo genome editing.

Which Firms Are Driving Innovation Within The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2025, By The Business Research Company

Cold Pain Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report

Physical Therapy Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/physical-therapy-software-global-market-report

Vitamin D Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795